Welcome to our dedicated page for Organon & Co. news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on Organon & Co. stock.
Organon & Co. (OGN) is a science-based global pharmaceutical company dedicated to developing and delivering essential health solutions. Founded in Oss, the Netherlands, Organon originally gained fame for pioneering the birth control pill, which revolutionized women's health. Over the years, the company expanded significantly and was acquired by Schering-Plough, and later by Merck, continuing its legacy as MSD in the Netherlands.
Today, Organon operates with a robust portfolio comprising women's health, biosimilars, and established medicines. The company focuses on providing prescription therapies that address a wide range of health needs, particularly in women's health. Organon's product offerings include innovations in contraception, fertility treatments, and menopause management.
In addition to women's health, Organon is committed to advancing the field of biosimilars - biologically similar products to existing branded drugs that promise to enhance patient access to key treatments. The company's established brands, which include a variety of well-known medications, continue to be a core revenue driver. Geographically, Organon derives most of its revenue from Europe and Canada, followed by the United States, and then the Asia Pacific and Japan regions.
Organon remains at the forefront of pharmaceutical innovation, driven by a mission to improve health outcomes globally. The company's strategic partnerships and continued investment in research and development reflect its commitment to addressing some of the most pressing health challenges of our time.
Organon reported third quarter 2022 revenues of $1,537 million, a 4% decline year-over-year. Diluted EPS from continuing operations was $0.89, down 30% from the previous year. Adjusted EBITDA stood at $546 million, down 11% year-over-year, reflecting higher costs and R&D expenditures. The women's health segment grew by 19%, while established brands saw a 11% decline. The company declared a quarterly dividend of $0.28 per share. Full year revenue guidance was narrowed to $6.1 billion to $6.2 billion.
Organon (NYSE: OGN) will announce its third quarter 2022 financial results on November 3, 2022, before a conference call at 8:30 a.m. EDT. The event can be accessed via a webcast on the company’s website, with a replay available shortly after. Organon focuses on improving women’s health and has a diverse portfolio of over 60 products, supported by strong cash flows. With a significant global presence, the company aims to expand its biosimilars business and collaborate with biopharmaceutical innovators.
Samsung Bioepis and Organon announced FDA approval for HADLIMA™ (adalimumab-bwwd), a citrate-free, high-concentration formulation of the adalimumab biosimilar referencing HUMIRA®. It will be available in pre-filled syringes and autoinjectors, enhancing treatment options for patients with chronic autoimmune diseases. This high-concentration version builds on the previous approval of a 50 mg/mL formulation in July 2019. The launch is expected on or after July 1, 2023, aiming to provide a more affordable alternative to the currently high-cost adalimumab in the U.S.
Organon (NYSE: OGN) reported Q2 2022 revenues of $1,585 million, a 1% decrease year-over-year but a 5% rise when excluding foreign currency impacts. The company recorded diluted EPS of $0.92 and adjusted EPS of $1.25, which faced a $0.30 negative impact due to acquired IPR&D costs. Adjusted EBITDA was $512 million with a margin of 32.3%. The board declared a quarterly dividend of $0.28 per share. The full-year revenue guidance has been updated to a range of $6.1 billion to $6.3 billion, reflecting ongoing foreign currency challenges.
Organon (NYSE: OGN) announced a research collaboration and exclusive license agreement with Cirqle Biomedical to develop a novel non-hormonal contraceptive. This investigational candidate aims to address the unmet needs of women seeking non-hormonal options. Organon will obtain exclusive rights to develop and commercialize the product, with Cirqle receiving a $10 million upfront payment and potential milestone payments of up to $360 million. The collaboration aligns with Organon’s focus on innovation in women’s health, as highlighted by its commitment to new contraceptive solutions.
Organon (NYSE: OGN) will release its second quarter 2022 financial results on August 4, 2022, prior to a conference call scheduled for 8:30 a.m. EDT. The call will be accessible via webcast on the company's website, and a replay will be available two hours post-event. Organon focuses on women's healthcare with over 60 medicines and products in its portfolio. The company aims to improve women's health through innovation and partnerships in growing international markets.
Cognizant (NASDAQ: CTSH) has entered a multi-year agreement with Organon (NYSE: OGN) to enhance the delivery of healthcare products and improve supply chain management. The partnership involves providing industrial technology support at Organon's manufacturing sites across the UK, Netherlands, Belgium, and Indonesia, utilizing SAP's S4/HANA suite. This collaboration aims to boost manufacturing efficiency, increase medicinal yields, and reduce cycle times, facilitating faster access to vital therapies for women's health.
Organon (NYSE: OGN) has announced a licensing agreement with Shanghai Henlius Biotech for the commercialization of biosimilars referencing Perjeta® (HLX11) and Prolia®/Xgeva® (HLX14). This collaboration reinforces Organon's commitment to expanding its biosimilars portfolio, particularly in women's health, focusing on treatments for breast cancer and osteoporosis. The deal includes a $73 million upfront payment and milestone payments based on achievements. This strategy aligns with Organon's goal to enhance patient access to these critical therapies.
Organon reported first quarter 2022 revenue of $1,567 million, a 4% increase from the previous year. Net income from continuing operations was $348 million or $1.36 per diluted share, reflecting a 12% decline year-over-year. The company’s adjusted net income was $420 million or $1.65 per diluted share, down 7%. Organon continues to grow its women's health offerings and affirmed its full-year financial guidance. A quarterly dividend of $0.28 was declared, payable on June 16, 2022.
FAQ
What is the current stock price of Organon & Co. (OGN)?
What is the market cap of Organon & Co. (OGN)?
What is Organon & Co. known for?
What are the main product areas of Organon & Co.?
Where does Organon & Co. generate most of its revenue?
Who previously acquired Organon & Co.?
What types of products does Organon offer in women's health?
What are biosimilars?
How does Organon & Co. contribute to global health?
Has Organon & Co. been involved in any recent significant projects or initiatives?
What is the history of Organon & Co. in the Netherlands?
What is the significance of Organon's established brands?
